MBRX 2.67 (+1.91%)
US60855D2009BiotechnologyBiotechnology

Moleculin Biotech (MBRX) Stock Highlights

2.67 | +1.91%
2024-11-21 06:37:47
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Statistics

Range Today
2.61 2.84
Volume Today 33.7K
Range 1 Year
0.4 6.24
Volume 1 Year 20.81M
Range 3 Year
0.34 6.24
Volume 3 Year 95.01M
Range 10 Year
0.34 57.48
Volume 10 Year 582.3M

Highlights

Market Capitalization 7.25M (micro)
Floating Shares 2.33M
Current Price 2.67
Price To Earnings -0.19
Price To Book 0.37
Earnings Per Share -12.78
Payout Ratio 0%

Performance

Latest +1.91%
1 Month +3.49%
3 Months +12.18%
6 Months -46.71%
1 Year +368.42%
3 Years +23.04%
5 Years -57.62%
10 Years -95.05%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.